Paul Tien
Acute Care · Houston, TXNPI 1134792070
Payments from drug & device makers
Across 69 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$349
- Sumitomo Pharma America, Inc.$224
- Johnson & Johnson$199
- Boston Scientific$140
- Convatec Inc.$115
- Urovant Sciences Inc$114
- plus $583 from 16 others
What the payments were for
- Food & beverage$1,52488%
- Education$19912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 11 | $349 |
| Sumitomo Pharma America, Inc. | 12 | $224 |
| Johnson & Johnson | 9 | $199 |
| Boston Scientific | 1 | $140 |
| Convatec Inc. | 5 | $115 |
| Urovant Sciences Inc | 6 | $114 |
| Pfizer | 5 | $110 |
| Progenics Pharmaceuticals, Inc. | 1 | $98 |
| Dendreon Pharmaceuticals LLC | 2 | $57 |
| Merck | 2 | $46 |
| Checkpoint Surgical, Inc | 1 | $41 |
| 180 Medical, Inc. | 2 | $38 |
| Tolmar, Inc. | 2 | $29 |
| Bayer | 2 | $26 |
| Ambu Inc. | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Smith+Nephew | 1 | $19 |
| Endo USA, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Innovation Technologies Inc | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
How this compares
$1,723 in reported general payments places this provider in the 80th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 12 | $130 |
Paid to pharmacies, not to this prescriber.
Other acute care in Houston
- Afton DickersonHouston$27K
- Eleanor WeltgeHouston$25K
- Leslie GutierrezHouston$25K
- Michelle JohnstonHouston$18K
- Amanda BergeronHouston$12K
- Nicole OnaHouston$12K
- Prashanth AnumandlaHouston$12K
- Ken ChanHouston$11K
- Brittney RichardHouston$11K
- Antonio Paolo AlmacenHouston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.